Bicara's development strategy centers on ficerafusp alfa for solid tumors. Key clinical focus areas include FORTIFI-HN01 (a Phase 2/3 trial in head and neck cancer) with enrollment expected to support an interim analysis in mid-2027 for potential accelerated filing, plus expansion cohorts in colorectal cancer. The dual-targeting approach addresses both tumor-intrinsic and immune-suppressive mechanisms in hard-to-treat cancers.
Cyborg Score Rationale
Preliminary Phase 1b data showed 57% confirmed ORR and 29% of responders with deep tumor shrinkage in head and neck cancer. The company has $362M from recent IPO funding, strong clinical momentum in high-need oncology indications, but remains pre-commercial with significant execution risk.
Top Insights
Ficerafusp alfa targets dual pathways: EGFR (tumor proliferation) and TGF-beta (immunosuppression), potentially differentiating from single-mechanism competitors
FORTIFI-HN01 Phase 2/3 trial expects substantial enrollment by end-2026 with interim analysis mid-2027 supporting accelerated filing potential
Multiple data readouts planned for 2026 including Phase 1b colorectal cancer expansion cohort and optimal dose selection in Q1 2026
Recently selected 1500 mg weekly dosing for pivotal trial based on biomarker data showing superior TGF-β inhibition and immune activation
Named Competitors
Pembrolizumab (Keytruda) — PD-1 checkpoint inhibitor for multiple cancer types
Opdivo — PD-1/PD-L1 checkpoint inhibitor in oncology
REGN2810 (Cemiplimab) — PD-1 inhibitor for advanced cancers
Recent Developments
(December 2025) Presented Phase 1b expansion data showing 57% ORR in HPV-negative head and neck cancer with ficerafusp alfa 750mg plus pembrolizumab
(January 2026) CEO presentation at J.P. Morgan Healthcare Conference
(September 2024) Completed $362M IPO at $18.00/share, commencing NASDAQ trading under ticker BCAX
Open the full interactive Bicara Therapeutics Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.